Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc (SNDX): 18 pipeline candidates · 3 upcoming catalysts · ~22 mo cash runway · 13 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
22.4 months
D/E 10.36 · 0% dilution
Lead: Phase 1/Phase 2
18 candidates
3 upcoming, next in ~1658d
0 buys · 6 sells (180d)
A transparent, data-derived signal for Syndax Pharmaceuticals Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$130.9M
Quarterly Burn
$50.3M
Runway
22.4 mo
Revenue
$64.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| ASTX727 | Phase 1 |
| Axatilimab | Phase 1 |
| Blinatumomab | Phase 1 |
| Chemotherapy | Phase 1 |
| Chemotherapy Regimen | Phase 1 |
| cobicistat | Phase 1/Phase 2 |
| Cytarabine | Phase 1 |
| Daunorubicin | Phase 1 |
| Entinostat | Phase 1 |
| HiDAC | Phase 1 |
Showing 10 of 18 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
243
Total value held
$2.15B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,254,426 | $192.8M |
| vanguard capital management llc | 7,645,158 | $178.6M |
| goldman sachs group inc | 4,996,787 | $116.7M |
| state street corp | 4,430,076 | $103.5M |
| bank of america corp /de/ | 4,249,836 | $99.3M |
| deerfield management company, l.p. | 3,779,900 | $88.3M |
| woodline partners lp | 2,501,520 | $58.4M |
| kingdon capital management, l.l.c. | 2,500,000 | $58.4M |
| stempoint capital lp | 2,731,486 | $57.0M |
| geode capital management, llc | 2,157,058 | $50.4M |
Showing top 10 of 243 institutional holders of Syndax Pharmaceuticals Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Syndax Pharmaceuticals Inc's pipeline?
Syndax Pharmaceuticals Inc (SNDX) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Syndax Pharmaceuticals Inc's lead drug candidate?
Syndax Pharmaceuticals Inc's most advanced tracked candidate is ASTX727 (Phase 1) for Acute Myeloid Leukemia.
What is Syndax Pharmaceuticals Inc's next catalyst?
Syndax Pharmaceuticals Inc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Inten" — expected January 1, 2031.
What is Syndax Pharmaceuticals Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Syndax Pharmaceuticals Inc has approximately 22.4 months of cash runway.
What is Syndax Pharmaceuticals Inc's market capitalization?
Syndax Pharmaceuticals Inc's market capitalization is approximately $1.7B.
Get the full picture on Syndax Pharmaceuticals Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.